Evaluation of the analytical sensitivity of ACON and LumiraDx SARS-CoV-2 rapid antigen tests using samples with presumed Omicron variant

Karon, Brad S.; Donato, Leslie J.; Moyer, Ann M.; Wockenfus, Amy M.; Kelley, Brandon R.; Majumdar, Ramanath; Kipp, Benjamin R.; Yao, Joseph D.

doi:10.1016/j.diagmicrobio.2023.115977

Diagnostic Microbiology and Infectious Disease

2023

DOI: 10.1016/j.diagmicrobio.2023.115977

|View full text |Cite

Evaluation of the analytical sensitivity of ACON and LumiraDx SARS-CoV-2 rapid antigen tests using samples with presumed Omicron variant

Brad S. Karon¹,

Leslie J. Donato²,

Ann M. Moyer³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Assessing the performance of LumiraDx™ SARS-CoV-2 Ag test in detecting Omicron lineages: 2022–2023 study

Cocchio,

Nicoletti,

Cozzolino

et al. 2024

Heliyon

View full text Add to dashboard Cite

Assessing the performance of LumiraDx™ SARS-CoV-2 Ag test in detecting Omicron lineages: 2022–2023 study

Cocchio,

Nicoletti,

Cozzolino

et al. 2024

Heliyon

View full text Add to dashboard Cite

Testing for SARS-CoV-2: lessons learned and current use cases

Theel,

Kirby,

Pollock

2024

Clin Microbiol Rev

View full text Add to dashboard Cite

SUMMARY The emergence and worldwide dissemination of SARS-CoV-2 required both urgent development of new diagnostic tests and expansion of diagnostic testing capacity on an unprecedented scale. The rapid evolution of technologies that allowed testing to move out of traditional laboratories and into point-of-care testing centers and the home transformed the diagnostic landscape. Four years later, with the end of the formal public health emergency but continued global circulation of the virus, it is important to take a fresh look at available SARS-CoV-2 testing technologies and consider how they should be used going forward. This review considers current use case scenarios for SARS-CoV-2 antigen, nucleic acid amplification, and immunologic tests, incorporating the latest evidence for analytical/clinical performance characteristics and advantages/limitations for each test type to inform current debates about how tests should or should not be used.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Evaluation of the analytical sensitivity of ACON and LumiraDx SARS-CoV-2 rapid antigen tests using samples with presumed Omicron variant

Cited by 2 publications

References 24 publications

Assessing the performance of LumiraDx™ SARS-CoV-2 Ag test in detecting Omicron lineages: 2022–2023 study

Assessing the performance of LumiraDx™ SARS-CoV-2 Ag test in detecting Omicron lineages: 2022–2023 study

Testing for SARS-CoV-2: lessons learned and current use cases

Contact Info

Product

Resources

About